Author:
Lamb Yvette N.,Scott Lesley J.,Deeks Emma D.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference8 articles.
1. European Medicines Agency. Flixabi: EU prescribing information. 2016.
http://www.ema.europa.eu/
. Accessed 27 July 2017.
2. Samsung Bioepis. Samsung Bioepis obtains first drug approval in the United States, as the U.S. Food and Drug Administration approves RENFLEXIS™ (Infliximab-abda) across all eligible indications [media release]. 2017.
http://www.samsungbioepis.com
. Accessed 27 July 2017.
3. European Medicines Agency. Flixabi CHMP assessment report. 2016.
http://www.ema.europa.eu/
. Accessed 27 July 2017.
4. Hong J, Lee Y, Lee C, et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab). mAbs. 2017;9(2):365–83.
5. Choe J-Y, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:58–64.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献